Skip to main content
Springer Nature Link
Log in

Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Dedifferentiated liposarcoma (DDLPS) is a highly aggressive subtype of liposarcoma that is histologically a transition form between an atypical lipomatous tumor/well-differentiated liposarcoma and a non-lipogenic sarcoma. DDLPS is genetically characterized by a complex karyotype with copy number variations and genomic complexity. DDLPS has a poor prognosis, a high local recurrence rate, and refractory behaviors for chemotherapy and radiation, which indicate a requirement for a novel therapeutic strategy for better clinical outcomes. We report here, a novel DDLPS cell line (NCC-DDLPS2-C1) developed from a tumor tissue. NCC-DDLPS2-C1 cells showed an amplified 12q13-15 region and exhibited constant growth, spheroid formation, and invasion. High-throughput drug screening revealed distinct sensitivity between monolayer- and three-dimensional cells. Romidepsin and trabectedin especially showed high anti-proliferative effects in both culture methods of NCC-DDLPS2-C1. Thus, the NCC-DDLPS2-C1 cell line may serve as a useful resource for DDLPS studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. Soft tissue and bone tumours. 4th ed. Geneva: WHO Press; 2020.

    Google Scholar 

  2. Saâda-Bouzid E, Burel-Vandenbos F, Ranchère-Vince D, et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Mod Pathol. 2015;28:1404–14.

    Article  Google Scholar 

  3. Italiano A, Bianchini L, Gjernes E, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res. 2009;15:5696–703.

    Article  CAS  Google Scholar 

  4. Snyder EL, Sandstrom DJ, Law K, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol. 2009;218:292–300.

    Article  CAS  Google Scholar 

  5. Erickson-Johnson MR, Seys AR, Roth CW, et al. Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Mod Pathol. 2009;22:1541–7.

    Article  CAS  Google Scholar 

  6. Abeshouse A, Adebamowo C, Adebamowo SN, Akbani R, Akeredolu T, Ally A, et al. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(950–65):e28.

    Google Scholar 

  7. Mariani O, Brennetot C, Coindre JM, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell. 2007;11:361–74.

    Article  CAS  Google Scholar 

  8. Kanojia D, Nagata Y, Garg M, et al. Genomic landscape of liposarcoma. Oncotarget. 2015;6:42429–44.

    Article  Google Scholar 

  9. Hirata M, Asano N, Katayama K, et al. Integrated exome and RNA sequencing of dedifferentiated liposarcoma. Nat Commun. 2019;10:5683.

    Article  CAS  Google Scholar 

  10. Thway K, Jones RL, Noujaim J, Zaidi S, Miah AB, Fisher C. Dedifferentiated liposarcoma: updates on morphology, genetics, and therapeutic strategies. Adv Anat Pathol. 2016;23:30–40.

    Article  CAS  Google Scholar 

  11. Assi T, Kattan J, Rassy E, et al. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: a comprehensive review. Critical RevOncol/Hematol. 2020;153:103029.

    Article  Google Scholar 

  12. Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13:1133–40.

    Article  CAS  Google Scholar 

  13. Mattei JC, Bouvier-Labit C, Barets D, et al. Pan aurora kinase inhibitor: a promising targeted-therapy in dedifferentiated liposarcomas with differential efficiency depending on sarcoma molecular profile. Cancers. 2020;12(3):583.

    Article  CAS  Google Scholar 

  14. Seligson ND, Stets CW, Demoret BW, et al. Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma. Oncotarget. 2019;10:5671–9.

    Article  Google Scholar 

  15. Keung EZ, Lazar AJ, Torres KE, et al. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018;18:913.

    Article  CAS  Google Scholar 

  16. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10:241–53.

    Article  CAS  Google Scholar 

  17. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15:747–56.

    Article  CAS  Google Scholar 

  18. Kondo T. Current status and perspectives of patient-derived rare cancer models. Hum Cell. 2020;33:919–29.

    Article  Google Scholar 

  19. Kondo T. Current status and future outlook for patient-derived cancer models from a rare cancer research perspective. Cancer Sci. 2020;. https://doi.org/10.1111/cas.14669.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.

    Article  CAS  Google Scholar 

  21. Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166:740–54.

    Article  CAS  Google Scholar 

  22. Teicher BA, Polley E, Kunkel M, et al. Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. Mol Cancer Ther. 2015;14:2452–62.

    Article  CAS  Google Scholar 

  23. Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a cancer dependency map. Cell. 2017;170:564–76.

    Article  CAS  Google Scholar 

  24. Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25–38.

    Article  Google Scholar 

  25. Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma. Hum Cell. 2020;33:427–36.

    Article  Google Scholar 

  26. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004;5:557–72.

    Article  Google Scholar 

  27. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007;23:657–63.

    Article  CAS  Google Scholar 

  28. Willenbrock H, Fridlyand J. A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics. 2005;21:4084–91.

    Article  CAS  Google Scholar 

  29. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941–7.

    Article  CAS  Google Scholar 

  30. Billiau A, Edy VG, Heremans H, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977;12:11–5.

    Article  CAS  Google Scholar 

  31. Nath S, Devi GR. Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol Ther. 2016;163:94–108.

    Article  CAS  Google Scholar 

  32. Voissiere A, Jouberton E, Maubert E, et al. Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing. PLoS ONE. 2017;12:e0181340.

    Article  Google Scholar 

  33. Ou WB, Zhu J, Eilers G, et al. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status. Oncotarget. 2015;6:10510–20.

    Article  Google Scholar 

  34. Peltonen K, Kiviharju TM, Järvinen PM, Ra R, Laiho M. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment Cell Res. 2005;18:196–202.

    Article  CAS  Google Scholar 

  35. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–6.

    Article  CAS  Google Scholar 

  36. Haigentz M Jr, Kim M, Sarta C, et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol. 2012;48:1281–8.

    Article  Google Scholar 

  37. Amiri-Kordestani L, Luchenko V, Peer CJ, et al. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res. 2013;19:4499–507.

    Article  CAS  Google Scholar 

  38. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;5:57–60.

    Article  CAS  Google Scholar 

  39. Noonan AM, Eisch RA, Liewehr DJ, et al. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. Clin Cancer Res. 2013;19:3095–104.

    Article  CAS  Google Scholar 

  40. McGovern Y, Zhou CD, Jones RL. Systemic therapy in metastatic or unresectable well-differentiated/dedifferentiated liposarcoma. Front Oncol. 2017;7:292.

    Article  Google Scholar 

  41. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34:786–93.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Miss Yu Kuwata (Division of Rare Cancer Research, National Cancer Center) for her technical support and Yukiko Ogura (Division of Diagnostic Pathology, Tochigi Cancer Center) for their work in the histopathological examination for this study. We would like to thank the Tochigi Cancer Center Operating Room Nurse Team and the Secretary of the Medical Office for their assistance in processing and transporting samples. We would like to thank Editage (www.editage.jp) for English-language editing and constructive comments on the manuscript.

Funding

This research was supported by the Japan Agency for Medical Research and Development (grant number 20ck0106537h0001).

Author information

Authors and Affiliations

  1. Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Rei Noguchi, Yuki Yoshimatsu, Takuya Ono, Akane Sei & Tadashi Kondo

  2. Division of Diagnostic Pathology, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan

    Kaoru Hirabayashi

  3. Division of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan

    Iwao Ozawa

  4. Division of Musculoskeletal Oncology and Orthopaedics Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan

    Kazutaka Kikuta

Authors
  1. Rei Noguchi
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Yuki Yoshimatsu
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Takuya Ono
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Akane Sei
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Kaoru Hirabayashi
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Iwao Ozawa
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Kazutaka Kikuta
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Tadashi Kondo
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethics approval

The use of clinical materials was approved by the ethical committee of the National Cancer Center (2004-050) and Tochigi Cancer Center (A-493).

Informed consent

Written informed consent was obtained from all the participating patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noguchi, R., Yoshimatsu, Y., Ono, T. et al. Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma. Human Cell 34, 990–997 (2021). https://doi.org/10.1007/s13577-021-00497-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-021-00497-0

Keywords

Profiles

  1. Rei Noguchi View author profile